Alexion's Soliris approved by FDA from accelerated to regular approval Alexionís supplemental Biologics License Application providing regular approval for Soliris for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy has been approved by the FDA. This update reflects Alexionís fulfillment of post-marketing requirements, including the submission of confirmatory data from two additional prospective clinical trials, including one in pediatric patients with aHUS. The revised label now specifies important longer-term clinical benefit associated with chronic and sustained Soliris treatment with inclusion of results with two years of ongoing treatment in aHUS patients. The updated label also includes data on the use of Soliris treatment prior to use of supportive care with either plasma exchange or plasma in prospective clinical trials.
Alexion announces $500M share repurchase program Alexion Pharmaceuticals announced that the companyís board has authorized a new share repurchase program of up to $500M. The new share repurchase program will take effect upon completion of the companyís current program, which has approximately $22M remaining of its previously authorized $400M.